„Aby wiedzieli, gdzie gniazdo nasze leży i skąd przodków naszych originem mamy”. Genealogia Topolskich herbu Nałęcz z ziemi sanockiej z XVII wieku

Wiedza na temat własnego pochodzenia i koligacji rodzinnych była istotna dla przedstawicielu stanu szlacheckiego. Wyróżniało to szlachtę na tle pozostałych stanów społecznych,  także definiowało ich jako grupę. Wywody genealogiczne szlachta zamieszczała w księgach sądowych najczęściej po to, żeby udowodnić swoje szlachectwo. W siedemnastowiecznych księgach grodzkich sanockich rzadko można spotkać takie szlacheckie wywody genealogiczne. Wyjątkowym przykładem jest genealogia rodziny Topolskich. Artykuł stanowi analizę wywodu genealogicznego spisanego przez Sebastiana Topolskiego w 1646 roku

„Aby wiedzieli, gdzie gniazdo nasze leży i skąd przodków naszych originem mamy”. Genealogia Topolskich herbu Nałęcz z ziemi sanockiej z XVII wieku

Wiedza na temat własnego pochodzenia i koligacji rodzinnych była istotna dla przedstawicielu stanu szlacheckiego. Wyróżniało to szlachtę na tle pozostałych stanów społecznych,  także definiowało ich jako grupę. Wywody genealogiczne szlachta zamieszczała w księgach sądowych najczęściej po to, żeby udowodnić swoje szlachectwo. W siedemnastowiecznych księgach grodzkich sanockich rzadko można spotkać takie szlacheckie wywody genealogiczne. Wyjątkowym przykładem jest genealogia rodziny Topolskich. Artykuł stanowi analizę wywodu genealogicznego spisanego przez Sebastiana Topolskiego w 1646 roku

Skuteczność liposomalnej cytarabiny w leczeniu pierwotnego i wtórnego zajęcia ośrodkowego układu nerwowego w przebiegu chłoniaków nieziarniczych – ocena retrospektywna pacjentów leczonych w Klinice Hematologii UJ CM

Intrathecally-administered liposomal cytarabine (DepoCyte – slow release formula) is an efficient way of treatment in primary and secondary central nervous system (CNS) involvement in patients with non-Hodgkin lymphoma. Thirty-six patients with CNS lymphoma were analyzed. Median age was 48 years (18–73). There were 18 males and 18 females.In patients with lymphoma infiltrations circumscribed to cerebro-spinal fluid, intrathecal liposomal cytarabine alone allowed for 100% responses, with concomitant improvement of performance status (as assessed by Karnofsky score). None of the patients relapsed in CNS within an average observation time of 28 months.Intrathecal liposomal cytarabine combined with whole brain radiotherapy or/and CNS-penetrating chemotherapy allowed to obtain 85.7% cytological responses (90.9% in patients with primary CNS lymphoma): 50% CR and 28.6% PR. Patient's general status improved in 50% of patients.The treatment was well tolerated. Most of the associated adverse events (AE) were mild and moderate (grade 1–2 according to CTCAE); only 5.6% of AE were considered as severe. Headache was the most common complication; whereas cauda equina syndrome was considered as potentially the most dangerous condition. Transient cauda equina syndrome was observed in 1 patient (2.8% of all AEs)

Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

AimPolish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure. BackgroundDespite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile. Materials and methodsRetrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. ResultsAfter six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation. ConclusionNivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit

Real-world effectiveness of abobotulinumtoxinA (Dysport®) in adults with upper limb spasticity in routine clinical practice: an observational study

AbobotulinumtoxinA (aboBoNT-A, Dysport®) is used in clinical practice as a well-tolerated and effective therapy for muscle spasticity. AboBoNT-A has been shown to reduce upper and lower limb spastic paresis in clinical trials, demonstrating improvements in muscle tone and limb function. This open-label, multicentre, observational, non-interventional study was the first to investigate aboBoNT-A’s efficacy in adult patients with upper limb spasticity (ULS) in routine clinical practice in Poland. All enrolled patients received ≥1 aboBoNT-A injection cycles, per routine clinical practice (full analysis set, FAS), and ≥1 rehabilitation session. Patients attended a baseline visit (V1) and two follow-up visits (V2, V3) for retreatment, depending on the investigator’s assessment of individual patient needs, with a mean interval (SD) between injections of 4.4 (1.4) and 4.5 (1.2) months. The primary effectiveness endpoint was patient- and physician-based evaluation using the Clinical Global Impression-Improvement Scale (CGII), a validated 7-point scale (1 = very much improved to 7 = very much worse) relative to baseline. CGI-I has not previously been used as a primary endpoint in studies evaluating ULS. Secondary endpoints included muscle tone in shoulder, elbow, carpal joint, and finger muscles, measured by the Modified Ashworth Scale (MAS), and muscle strength according to the Medical Research Council scale (MRC). Of 108 enrolled patients (FAS), 92 (85.2%) completed the study and 57 (52.8%) were included in the per protocol (PP) population. AboBoNT-A improved patient conditions in 96.4% and 98.6% at V2 and V3 (investigator assessment) and 92.8% and 98.6% (as reported by patient) of patients, respectively. Significant reductions in muscle tone from baseline were observed at both visits (p < 0.0001–0.0077) across muscle groups. Increased muscle strength by cumulative MRC was observed at V2 (p = 0.0566) and V3 (p = 0.0282) versus baseline. Safety was consistent with the known profile of aboBoNT-A. In conclusion, aboBoNT-A treatment is beneficial in patients with post-stroke ULS in routine clinical practice, assessed by patients and investigators